Literature DB >> 24711168

Prognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer.

Anna Novell1, Montserrat Martínez-Alonso, Moises Mira, Jordi Tarragona, Antonieta Salud, Xavier Matias-Guiu.   

Abstract

Locally advanced rectal cancer (LARC) is associated with a 25 % rate of metastases. The prognostic and predictive relevances of the expression of five proteins (c-FLIPL/s, HIF-1α, β-catenin, p65, and p105/p50 NF-κβ) were assessed. This is a retrospective study. From 1998 to 2009, 152 patients with stage II/III rectal cancer were treated with radio-chemotherapy. TMAs constructed with tumor and normal tissue from the diagnostic endoscopic biopsy and the surgical specimen after chemoradiotherapy were subjected to immunohistochemical (IHC) analysis. Results were correlated with clinical and pathological data, including progression-free survival (PFS). Four different IHC conditions were independent prognostic parameters for PFS: (1) cytoplasmic c-FLIPL/s (p = 0.007), (2) nuclear HIF-1α (p = 0.020), (3) a change in the cytoplasmic p65 between the diagnostic biopsy and the post-treatment specimen (p = 0.004), and (4) a change in the cytoplasmic c-FLIPL/s between the diagnostic biopsy and the post-treatment specimen (p = 0.021). Three different protein expression profiles, combining biomarkers, showed prognostic significance. IHC evaluation of these biomarkers in our three protein expression profiles may help to identify patients with worse prognosis and design more effective therapeutic strategies to personalize the treatment of rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24711168     DOI: 10.1007/s00428-014-1572-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

Review 1.  Biomarkers in cancer staging, prognosis and treatment selection.

Authors:  Joseph A Ludwig; John N Weinstein
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

Review 2.  A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.

Authors:  Judit Pallares; Maria Santacana; Soraya Puente; Susana Lopez; Andree Yeramian; Nuria Eritja; Anabel Sorolla; David Llobet; Xavier Dolcet; Xavier Matias-Guiu
Journal:  Anal Quant Cytol Histol       Date:  2009-08       Impact factor: 0.302

3.  Activation of nuclear factor kappa B in Crohn's disease.

Authors:  R D Ellis; J R Goodlad; G A Limb; J J Powell; R P Thompson; N A Punchard
Journal:  Inflamm Res       Date:  1998-11       Impact factor: 4.575

4.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Authors:  Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

5.  Protein expression of NF-kappaB in human colorectal adenocarcinoma.

Authors:  Sofia Evertsson; Xioa-Feng Sun
Journal:  Int J Mol Med       Date:  2002-11       Impact factor: 4.101

6.  Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer.

Authors:  George E Theodoropoulos; Andreas C Lazaris; Vasilios E Theodoropoulos; Kalliopi Papatheodosiou; Maria Gazouli; John Bramis; Efstratios Patsouris; Dimitrios Panoussopoulos
Journal:  Int J Colorectal Dis       Date:  2005-07-29       Impact factor: 2.571

7.  Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis.

Authors:  Hong-Gang Yu; Liang-Liang Yu; Yanning Yang; He-Sheng Luo; Jie-Ping Yu; Juris J Meier; Henning Schrader; Andreas Bastian; Wolfgang E Schmidt; Frank Schmitz
Journal:  Oncology       Date:  2003       Impact factor: 2.935

8.  Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas.

Authors:  Daniela Furlan; Nora Sahnane; Ileana Carnevali; Roberta Cerutti; Francesco Bertoni; Ivo Kwee; Silvia Uccella; Valentina Bertolini; Anna Maria Chiaravalli; Carlo Capella
Journal:  Hum Pathol       Date:  2008-07-11       Impact factor: 3.466

9.  c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications.

Authors:  P Korkolopoulou; A A Saetta; G Levidou; F Gigelou; A Lazaris; I Thymara; M Scliri; K Bousboukea; N V Michalopoulos; N Apostolikas; A Konstantinidou; M Tzivras; E Patsouris
Journal:  Histopathology       Date:  2007-06-08       Impact factor: 5.087

Review 10.  NF-kappaB as a potential molecular target for cancer therapy.

Authors:  Chae Hyeong Lee; Yong-Tark Jeon; Su-Hyeong Kim; Yong-Sang Song
Journal:  Biofactors       Date:  2007       Impact factor: 6.113

View more
  1 in total

1.  Hypoxia attenuates the proinflammatory response in colon cancer cells by regulating IκB.

Authors:  Kamila Müller-Edenborn; Karolin Léger; Jesus F Glaus Garzon; Carole Oertli; Ali Mirsaidi; Peter J Richards; Hubert Rehrauer; Patrick Spielmann; David Hoogewijs; Lubor Borsig; Michael O Hottiger; Roland H Wenger
Journal:  Oncotarget       Date:  2015-08-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.